Jessie Burns

Dr. Jessie Burns

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Prostaglandins, Leukotrienes and Essential Fatty Acids
Verified
Journal Article
Closed access
JBJessie Burns
Jessie Burns
MNManabu T. Nakamura
Manabu T. Nakamura
DMDavid Ma
David Ma

1 September 2021 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
JMJennifer Monk
Jennifer Monk
DLDanyelle M. Liddle
Danyelle M. Liddle
AHAmber L. Hutchinson
Amber L. Hutchinson
JBJessie Burns
Jessie Burns
HWHannah Wellings
Hannah Wellings
DMDavid Ma
David Ma

4 February 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
AAAla Alzubi
Ala Alzubi
HGHannah X. Glowacki
Hannah X. Glowacki
JBJessie Burns
Jessie Burns
KVKelsey Van
Kelsey Van
JMJamie Martin
Jamie Martin
JMJennifer Monk
Jennifer Monk
Background: Short-chain fatty acids (SCFAs) produced from microbial fermentation of non-digestible carbohydrates and protein have been shown to modulate adipocyte adipokine secretion and metabolic function, which has implications for mitigating dysfunction in obese adipose tissue; however, the individual effects of different SCFAs and the optimal concentration required is unknown. The purpose of this study was to dose-dependently determine the effects of individual SCFAs on adipocyte adipokine secretion and metabolic function. Methods: We recapitulated the obese adipocyte inflammatory conditions using mature 3T3-L1 adipocytes and a physiological concentration of lipopolysaccharide (LPS) ± individual SCFAs, namely acetate, propionate, and butyrate, in a dose-dependent manner (0.25 mM, 0.5 mM, and 1 mM) for 24 h. Results: SCFAs dose-dependently affected inflammatory adipokine secretion, wherein at 1 mM, all three SCFAs reduced the secretion of leptin, IL-6 and IL-1β, but only propionate and butyrate reduced MCP-1/CCL2 and MIP-1α/CCL3 compared to control (p < 0.05). Interestingly, 1 mM acetate increased RANTES/CCL5 secretion versus control, whereas propionate and butyrate decreased RANTES/CCL5 secretion, and only 1 mM propionate reduced MCP-3/CCL7 secretion (p < 0.05). At the lower 0.5 mM concentration, both propionate and butyrate reduced IL-6 and IL-1β secretion compared to control (p < 0.05), and there was no difference in adipokine secretion between groups at the 0.25 mM SCFA concentration (p > 0.05). Intracellular protein expression in the ratio of phosphorylated–to–total STAT3 was reduced by all SCFAs at 1 mM and by propionate and butyrate at 0.5 mM versus control (p < 0.05). The ratio fo phosphorylated–to–total NFκB p65 expression was reduced by propionate and butyrate at 1 mM and by butyrate alone at 0.5 mM compared to control (p < 0.05). Basal (no insulin stimulation) and insulin-stimulated glucose uptake did not differ between control and any 1 mM SCFA treatment conditions (p > 0.05). Conclusions: Individual SCFAs exert different dose-dependent effects on LPS-stimulated adipocyte function.

18 August 2025 in Journal of Obstetrics and Gynaecology Canada
Verified
Journal Article
Closed access
DFDiane Francoeur
Diane Francoeur
JCJocelynn L. Cook
Jocelynn L. Cook
RWR. Douglas Wilson
R. Douglas Wilson
FPFrank Potestio
Frank Potestio
JBJessie Burns
Jessie Burns

17 March 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
JBJessie Burns
Jessie Burns
KVKelsey Van
Kelsey Van
AAAla Alzubi
Ala Alzubi
CCClara Cho
Clara Cho
JMJennifer Monk
Jennifer Monk
Background: Microbial fermentation of non-digestible carbohydrates and proteins produce short-chain fatty acids (SCFAs), which are critical communication signals in the gut–adipose tissue axis. Individual SCFA can differentially modulate the adipocyte secretory profile and adipose tissue metabolic function; however, their dose-dependent effects on adipocyte function in combined inflammatory and hypoxic environmental conditions that reflect the obesity-associated adipose tissue phenotype remain unknown. Methods: Mature 3T3-L1 adipocytes were cultured for 24 h with lipopolysaccharide (LPS; 10 ng/mL) plus 100 µM of cobalt chloride (CoCl2) to chemically induce hypoxia ± individual SCFAs, namely acetate (Ace), propionate (Pro), and butyrate (But), in a dose-dependent manner (0.25 mM, 0.5 mM, and 1 mM). Results: Ace, Pro and But reduced secretion of IL-6, MCP-1/CCL7 and Rantes/CCL5 in a dose-dependent manner, whereas Pro and But reduced MCP3/CCL7 secretion and only But reduced resistin and increased adiponectin secretion compared to control (p < 0.05). Intracellular protein expression of the ratio of phosphorylated–to–total NFκB p65 was reduced by 1 mM But, whereas the ratio of phosphorylated–to–total STAT3 expression was reduced by 1 mM Ace, Pro and But and 0.5 mM Pro and But compared to control (p < 0.05). There was no difference in insulin-stimulated or non-insulin-stimulated glucose uptake between control and any individual SCFAs (p > 0.05). Conclusions: Adipocyte adipokine secretory function in combined inflammation and hypoxic environmental conditions is dose-dependently attenuated by individual SCFA, which exhibit both individual and overlapping effects.

6 May 2026 in Marine Drugs
Verified
Journal Article
Open access
PDF file
AAAla Alzubi
Ala Alzubi
ALAlyssa Lucchesi
Alyssa Lucchesi
JBJessie Burns
Jessie Burns
CCClara Cho
Clara Cho
DMDavid Ma
David Ma
JMJennifer Monk
Jennifer Monk
Obesity is a complex metabolic disorder defined by a body mass index greater than 30 kg/m2, excess adipose tissue accumulation, chronic low-grade inflammation and metabolic dysfunction, leading to increased susceptibility to other chronic conditions. Evidence from both mechanistic pre-clinical studies and human clinical trial suggests a role for long-chain (LC) n-3 polyunsaturated fatty acids (PUFAs), namely eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), to modulate obesity-associated outcomes and attenuate the production of inflammatory mediators, namely adipokines from adipose tissue and myokines from skeletal muscle, that can mitigate inflammation-associated metabolic dysfunction. Therefore, this narrative review synthesizes evidence and mechanistic insights on the role(s) of n-3 PUFA in regulating obesity-associated changes in adipose tissue and skeletal muscle inflammation and immune cell trafficking and metabolic outcomes.